Tag: Pakistan

Posted on

Nyxoah to Participate in the Jefferies London Healthcare Conference

Nyxoah to Participate in the Jefferies London Healthcare Conference

Mont-Saint-Guibert, Belgium – October 20, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The Waldorf Hilton in London.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update during a fireside chat on Thursday, November 17, 2022, at 10:25am GMT. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.

Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

GlobeNewswire Distribution ID 1000752038

 

Posted on

TSP FINAL DEADLINE NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages TuSimple Holdings Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action – TSP

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TuSimple Holdings Inc. (NASDAQ: TSP): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about April 15, 2021 (the “IPO”); and/or (ii) between April 15, 2021 and August 1, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TuSimple securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TuSimple class action, go to https://rosenlegal.com/submit-form/?case_id=8026 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding TuSimple’s business, operations, and prospects. Specifically, the IPO documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) TuSimple’s commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company’s technology; (2) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (3) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (4) the aforementioned conduct made accidents involving TuSimple’s autonomous driving technology more likely; (5) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward TuSimple; and (6) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TuSimple class action, go to https://rosenlegal.com/submit-form/?case_id=8026 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8669564

Posted on

ABT FINAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors with Losses in Excess of $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Abbott securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) according to the U.S. Food and Drug Administration (“FDA”), Abbott had “egregiously unsanitary” conditions at its Sturgis, Michigan facility which produced nearing half of Abbott’s various forms of infant formula under the brands Similac, Alimentum, and EleCare; (2) as a result, Abbott’s infant formula business was in dire jeopardy given the flagrant violations of federal and state health and safety regulations; (3) based on inspections by the FDA between 2019 and 2022, Abbott failed to establish process controls “designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment” and Abbott also failed to “ensure that all surfaces that contacted infant formula were maintained to protect infant formula from being contaminated by any source”; (4) the unhygienic conditions of the Sturgis facility resulted in the recall of Abbott’s infant formula and closure of the Sturgis facility; and (5) as a result, defendants’ public statements about Abbott’s business, operations, and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Abbott class action, go to https://rosenlegal.com/submit-form/?case_id=8453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8669551

Posted on

HGEN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 25 Deadline in Securities Class Action – HGEN

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”) of the important October 25, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Humanigen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humanigen class action, go to https://rosenlegal.com/submit-form/?case_id=8376 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (2) as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the lenzilumab Emergency Use Authorization (“EUA”) and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (3) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (4) as a result, Humanigen’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Humanigen class action, go to https://rosenlegal.com/submit-form/?case_id=8376 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8669547

Posted on

AZRE FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Azure Power Global Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important October 31 Deadline in Securities Class Action – AZRE

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Azure Power Global Limited (NYSE: AZRE) between June 15, 2021 and August 26, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Azure Power securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Azure Power class action, go to https://rosenlegal.com/submit-form/?case_id=8433 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about Azure Power’s business operations and prospects. Specifically, defendants failed to disclose to investors that: (1) there were procedural irregularities, including deviations from safety and quality standards, at one of Azure Power’s plants; (2) certain project data was manipulated; (3) as a result of the foregoing, Azure Power’s internal controls and procedures were not effective; (4) Azure Power had received a credible whistleblower report alleging such misconduct; and (5) as a result of the foregoing, defendants’ positive statements about Azure Power’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Azure Power class action, go to https://rosenlegal.com/submit-form/?case_id=8433 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8669548

Posted on

Quantexa Has Been Positioned by Chartis as a Category Leader in the KYC Solutions 2022 Market Quadrant Update and Vendor Landscape

Quantexa’s KYC Solution, part of its industry leading Decision Intelligence Platform, recognized for completeness of offering, risk scoring, customer profile enrichment, and customer onboarding

LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) — Today Quantexa, a global data and analytics software company pioneering Contextual Decision Intelligence (CDI) and helping the world’s leading organizations and government agencies solve some of their toughest data challenges, announced that they have been recognized as a category leader in the just released 2022 Chartis KYC Solutions Market Update and Vendor Landscape report. Quantexa is being recognized as a category leader for completeness of their enterprise solution as well as market potential. The Quantexa KYC Solution was rated “best in class” for KYC risk scoring and customer profile enrichment with additional data and received an advanced ranking for customer onboarding and reporting, and dashboarding.

The Chartis KYC report is focused on the macro themes of cost saving and efficiency. Currently, KYC processes can be manual, error-prone and result in a poor experience throughout the customer lifecycle. Quantexa’s Decision Intelligence Platform transforms the approach to KYC by adding context and clarity from onboarding to exit, dynamically monitoring, and assessing customer risk and opportunity, and shifting away from manual periodic reviews to an automated, proactive process.

The platform connects internal and external data to create a single, enriched, holistic view of a customer and its control, and uncovers hidden connections between customers, counterparties and their behaviors which are often impossible to see in isolation. Along with automation and the use of AI to achieve efficiencies, the solution facilitates a continuous and informed understanding of customers for better, faster decision making throughout the customer acceptance, identification, activity monitoring, and risk management processes.

Quantexa’s positioning in the report is reflective of their customers’ proven results and is proof that adopting a contextual and perpetual approach to KYC reduces the time and costs involved for businesses. It also transforms what has become a tick-the-box exercise, back into the true purpose of understanding the risk and exposure brought on by customer activity. By increasing automation and using decision intelligence, businesses stay ahead of the volume and velocity of data related to KYC policies and processes and can free up their teams, so they have more time to concentrate on high-risk customers and value-add tasks.

Quote: Phillip Mackenzie, Senior Research Specialist, Chartis
“The Chartis RiskTech Quadrant for KYC does not simply describe one technology solution as the best – rather, we use the most sophisticated ranking methodology to explain which solution would be most suitable for buyers, depending on their implementation strategies. Our research finds that Quantexa’s KYC Solution offers businesses the necessary controls to address the risks involved in using AI in their compliance programs.”

Quote: Dan Higgins, Chief Product Officer, Quantexa

“Quantexa is thrilled to be included in the Chartis KYC Market Quadrant Report, positioned very strongly amongst an esteemed list of enterprise solution providers. Traditional ongoing due diligence and periodic refreshes of KYC continue to drive cost and complexity for businesses. The increasing regulatory, budget and customer pressures demand a new way of thinking. Quantexa’s contextual approach reduces the time and cost of KYC by increasing automation, connecting non-obvious relationships, and leveraging decision intelligence for perpetual monitoring of risk. This translates into more accurate risk identification and management, lower costs, and improved customer experience. We are confident that this approach will continue to provide value to our clients and drive overall market growth for Quantexa.”

ABOUT QUANTEXA
Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 500 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, New York, Boston, Washington DC, Brussels, Toronto, Singapore, Melbourne, and Sydney. For more information, contact Quantexa here or follow us on LinkedIn.

ABOUT CHARTIS

Chartis is a research and advisory firm that provides technology and business advice to the global risk management industry. Chartis provides independent market intelligence regarding market dynamics, regulatory trends, technology trends, best practices, competitive landscapes, market sizes, expenditure priorities, and mergers and acquisitions. Chartis’ RiskTech Quadrant reports are written by experienced analysts with hands-on experience of selecting, developing and implementing risk management systems for a variety of international companies in a range of industries, including banking, insurance, capital markets, energy and the public sector.

A PDF accompanying this announcement is available at:

http://ml-eu.globenewswire.com/Resource/Download/0b256614-6827-4dd7-b1fe-d9c1df5bb360

Media Inquiries:

C: Laurel Case, VP, Fight or Flight
T: +1 315 663 6780
E: Quantexa@fightflight.co.uk

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
– or –
RapidResponse@quantexa.com